Apart from camrelizumab, tislelizumab, one of the four domestically made PD-1 antibodies reported an 80% discount for landing on China's reimbursement list in 2020, had been approved for advanced non-squamous NSCLC recently. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.